Cargando…
Different impact of factor VIII products on inhibitor development?
Inhibitors are the most serious side effect of haemophilia treatment; they occur in 25–30 % of all patients with severe haemophilia A. Over the last 2 decades, conflicting data on the impact of clotting products have been published. Due to small studies of selected cases, appreciation of the impact...
Autor principal: | van den Berg, H. Marijke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056474/ https://www.ncbi.nlm.nih.gov/pubmed/27766057 http://dx.doi.org/10.1186/s12959-016-0102-4 |
Ejemplares similares
-
Repression of Factor VIII Inhibitor Development with Apoptotic Factor VIII-expressing Embryonic Stem Cells
por: Sakurai, Yoshihiko, et al.
Publicado: (2013) -
Models for Prediction of Factor VIII Half-Life in Severe Haemophiliacs: Distinct Approaches for Blood Group O and Non-O Patients
por: Fischer, Kathelijn, et al.
Publicado: (2009) -
Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX
por: Rocino, Angiola, et al.
Publicado: (2017) -
Impact of different factor VIII inhibitor kinetic profiles on the inhibitor titer quantification using the modified Nijmegen–Bethesda assay
por: Ketteler, Carolin, et al.
Publicado: (2022) -
Acquired Factor VIII Inhibitors: Three Cases
por: Kyaw, Tay Za, et al.
Publicado: (2013)